AG
ALXO icon

Artal Group’s ALX Oncology ALXO Stock Holding History

Artal Group’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-500,000
Closed -$3.75M – 104
2023
Q2 		$3.75M Hold
500,000
– – 0.12% 72
2023
Q1 		$2.26M Hold
500,000
– – 0.13% 77
2022
Q4 		$5.63M Hold
500,000
– – 0.31% 58
2022
Q3 		$4.79M Hold
500,000
– – 0.2% 62
2022
Q2 		$4.04M Hold
500,000
– – 0.22% 65
2022
Q1 		$8.45M Hold
500,000
– – 0.35% 55
2021
Q4 		$10.7M Hold
500,000
– – 0.29% 68
2021
Q3 		$36.9M Hold
500,000
– – 0.83% 30
2021
Q2 		$27.3M Sell
500,000
-25,000
-5% -$1.5M 0.55% 40
2021
Q1 		$38.7M Buy
525,000
+225,000
+75% +$17.7M 0.68% 31
2020
Q4 		$25.9M Buy
300,000
+200,000
+200% +$12M 0.56% 49
2020
Q3 		$3.77M Buy
+100,000
New +$3.93M 0.09% 106

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Artal Group's ALXO Position: Q3 2023 in Review

Artal Group sold out of ALX Oncology (ALXO) in Q3 2023, closing a stake of 500,000 shares — an estimated $3.75M sold.

Artal Group first reported a position in ALXO in Q3 2020 and held it in 12 quarters. The position peaked at $38.7M in Q1 2021. 76 funds tracked by Wall St. Rank hold ALXO as of Q3 2023.

  • Artal Group reported no remaining ALX Oncology position as of Q3 2023 after selling out during the quarter.
  • Artal Group sold 500,000 ALX Oncology shares in Q3 2023, an estimated $3.75M.
  • Artal Group first reported a position in ALX Oncology in Q3 2020 and held it in 12 quarters.
  • Artal Group's ALX Oncology position peaked at $38.7M in Q1 2021.
  • 76 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2023.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.